Considerations for Generating Clinical Evidence from Oncology Multiregional Clinical Development Programs
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
September 16, 2024
September 16, 2024
78fa8deb-dab7-4321-a08d-f5971e107619
Related Documents
Tissue Agnostic Drug Development in Oncology: Draft Guidance for Industry
Guidance DocumentOctober 17, 2022Office of the Commissioner
Considerations in Demonstrating Interchangeability With a Reference Product: Update
Guidance DocumentJune 21, 2024Center for Drug Evaluation and Research
Clinical Trial Considerations to Support Accelerated Approval of Oncology Therapeutics
Guidance DocumentMarch 24, 2023Office of the Commissioner
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Stay ahead of FDA enforcement
New KeyPedia insights, webinars, and regulatory analysis — straight to your inbox. Unsubscribe anytime.